Tadalafil / Vardenafil

Hard-Tab (mint)

20 mg / 8 mg

Ready to prescribe?
Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Tadalafil1-3

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor with a mean terminal half-life exceeding 17 hours, which is considerably longer than that of other PDE5 inhibitors. This extended half-life allows for either once-daily or on-demand dosing. Tadalafil is indicated for the treatment of pulmonary arterial hypertension (PAH), erectile dysfunction (ED), benign prostatic hyperplasia (BPH), or for the concurrent management of ED and BPH.

Vardenafil4-6  

Vardenafil is a potent and highly selective oral PDE5 inhibitor with a mean terminal half-life of 4 to 6 hours. It is generally well tolerated and is indicated for the treatment of erectile dysfunction, typically used on an on-demand basis.

Tadalafil,2,3

Phosphodiesterase (PDE) has many isoforms and is an enzyme that has many functions in the body including degrading the effect of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). PDE5 is an enzyme that is found in many parts of the body including in the smooth muscle of the corpus cavernosum, prostate, bladder, the vascular and visceral smooth muscle, skeletal muscle, urethra, platelets, kidney, lung, cerebellum, heart, liver, testis, seminal vesicle, and pancreas. Tadalafil is a selective inhibitor of PDE5, the enzyme responsible for the degradation of cGMP. The drug has selective activity on PDE5 than other phosphodiesterase isoforms. Tadalafil activity on PDE5 is more than 10,000-fold more than for PDE1, PDE2, PDE4, and PDE7 enzymes. Increased cGMP leads to smooth muscle relaxation in the corpus cavernosum which can help in maintaining an erection.

Vardenafil4-6

Phosphodiesterase (PDE) has many isoforms and is an enzyme that has many functions in the body including degrading the effect of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). PDE5 is an enzyme that is found in many parts of the body including in the smooth muscle of the corpus cavernosum, prostate, bladder, the vascular and visceral smooth muscle, skeletal muscle, urethra, platelets, kidney, lung, cerebellum, heart, liver, testis, seminal vesicle, and pancreas. Vardenafil is a selective inhibitor of PDE5, the enzyme responsible for the degradation of cGMP. Vardenafil’s activity on PDE5 has been shown to be approximately 10 fold to 25 fold more than sildenafil. Increased cGMP leads to smooth muscle relaxation in the corpus cavernosum which can help in maintaining an erection.

Common 

Tadalafil1,2

  • Headache
  • Dyspepsia
  • Flushing
  • Back pain and myalgia (typically delayed onset, resolving within 48 hours)
  • Nasal congestion
  • Pain in limbs

 

Vardenafil4,5 

  • Headache
  • Flushing
  • Rhinitis
  • Dyspepsia, vomiting
  • Dizziness

Contraindications 1,2,4,5

  • Known hypersensitivity to tadalafil, vardenafil or tablet excipients
  • Use of nitrates and guanylate cyclase (GC) stimulators therapy, such as riociguat due to risk of life-threatening hypotension

Precautions 1,2,4,5

  • Use with caution in patients with:
  • Severe hepatic impairment (Child-Pugh Class C)
  • Severe renal impairment (creatinine clearance <30 mL/min)
  • Retinitis pigmentosa (rare inherited retinal disorder)
  • History of NAION (non-arteritic anterior ischemic optic neuropathy)
  • Recent history of myocardial infarction, stroke, or unstable angina
  • Store at controlled room temperature (20°C to 25°C / 68°F to 77°F)
  • Protect from moisture and light
  • Keep in a tightly closed container
  1. Tadalafil Prescribing Information – Eli Lilly. www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf Revised October 2011. Accessed May 31, 2025
  2. Clinical Pharmacology Tadalafil clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  3. Padda IS, Tripp J. Phosphodiesterase Inhibitors. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559276/
  4. Clinical Pharmacology Vardenafil clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  5. Vardenafil package insert. Bayer Healthcare Pharmaceuticals, Inc. Revised April 2014. Accessed June 12, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021400s017lbl.pdf.
  6. Keating GM, Scott LJ. Vardenafil: a review of its use in erectile dysfunction. Drugs. 2003;63(23):2673-703.

WPPL operates as a 503A compounding pharmacy and prepares individualized prescription medications pursuant to provider direction. Compounded preparations are not reviewed, tested, or approved by the FDA.

This listing also includes commercially manufactured products for convenience; these items are not compounded by our pharmacy and are sold as provided by their manufacturers. Actual products in stock at time of dispensing may vary due to supply chain variability. Any statements regarding non-compounded products are manufacturer-supplied, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease. WPPL does not verify or endorse any therapeutic claims made by manufacturers. Please refer to original labeling for complete product information.

EXPLORE MORE

Related Medications

Licensed to ship across the U.S.

Your orders arrive promptly and privately, delivered directly to your door.

Providers: Let’s Partner for Better Patient Care

If you are a physician, clinic, or practice seeking a dependable Compounding Pharmacy partner, WP Pharma Labs is here to help. With dedicated account setup, streamlined ordering and responsive service, we support your therapeutic goals with specialized compounds designed for your patients.

To check product availability, check on the status of an existing order, request refills:
orders@wppharmalabs.com

New providers setup / update an existing account:
newaccounts@wppharmalabs.com